

Resource Summary Report

Generated by T1D on Jul 31, 2026

Cancer Dependency Map Portal

RRID:SCR_017655

Type: Tool

Proper Citation

Cancer Dependency Map Portal (RRID:SCR_017655)

Resource Information

URL: <https://depmap.org/portal/>

Proper Citation: Cancer Dependency Map Portal (RRID:SCR_017655)

Description: Portal for identifying genetic and pharmacologic dependencies and biomarkers that predicts them by providing access to datasets, visualizations, and analysis tools that are being used by Cancer Dependency Map Project at Broad Institute. Project to systematically identify genes and small molecule dependencies and to determine markers that predict sensitivity. All data generated by DepMap Project are available to public under CC BY 4.0 license on quarterly basis and pre-publication.

Abbreviations: DepMap Portal

Synonyms: Dependency Map Portal, Dependency Map portal, Cancer DepMap, Cancer Dependency Map Project

Resource Type: data set, project portal, catalog, portal, data or information resource, database

Keywords: Cancer, vulnerability, dataset, visualization, analysis, tool, catalog, biomarker, genetic, drug, sensitivity, tumor, model, FASEB list

Availability: Free, Available for download, Freely available

Resource Name: Cancer Dependency Map Portal

Resource ID: SCR_017655

Record Creation Time: 20220129T080336+0000

Record Last Update: 20260731T043012+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Dependency Map Portal.

No alerts have been found for Cancer Dependency Map Portal.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1000 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Gou X, et al. (2026) Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells. *Cancer research communications*, 6(1), 5.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. *British journal of cancer*, 134(1), 141.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

van Kampen F, et al. (2025) Deletion of 17p in cancers: Guilt by (p53) association. *Oncogene*, 44(10), 637.

Schlesinger D, et al. (2025) A large-scale sORF screen identifies putative microproteins involved in cancer cell fitness. *iScience*, 28(3), 111884.

Ling J, et al. (2025) PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18. *Hepatology communications*, 9(4).

Masi M, et al. (2025) Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. *Cell death discovery*, 11(1), 106.

Zhong S, et al. (2025) Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy. *Clinical and translational medicine*, 15(3), e70177.

Esp??n R, et al. (2025) Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment. *NAR cancer*, 7(1), zcaf007.

Yang R, et al. (2025) Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer. *Journal of cellular and molecular medicine*, 29(5), e70384.

Li Y, et al. (2025) Identification and multi-omics analysis of essential coding and long non-coding genes in colorectal cancer. *Biochemistry and biophysics reports*, 41, 101938.

Liu Y, et al. (2025) Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age. *mAbs*, 17(1), 2470309.

Kougnassoukou Tchara PE, et al. (2025) Coupling Proximity Biotinylation with Genomic Targeting to Characterize Locus-Specific Changes in Chromatin Environments. *Journal of proteome research*, 24(4), 1845.

Christopher JA, et al. (2025) Global Proteomics Indicates Subcellular-Specific Anti-Ferroptotic Responses to Ionizing Radiation. *Molecular & cellular proteomics : MCP*, 24(1), 100888.

Wnuk M, et al. (2025) Design of a Magnetic Nanoplatfrom Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells. *ACS biomaterials science & engineering*, 11(1), 280.

Pollin G, et al. (2025) Emergent properties of the lysine methylome reveal regulatory roles via protein interactions and histone mimicry. *Epigenomics*, 17(1), 5.

Montella A, et al. (2025) Regulatory non-coding somatic mutations as drivers of neuroblastoma. *British journal of cancer*, 132(5), 469.

Chen L, et al. (2025) Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events. *Scientific reports*, 15(1), 3048.

Snaebjornsson MT, et al. (2025) Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation. *Nature metabolism*, 7(2), 348.